Here they identify a selective PRC1.1 inhibitor, iBP, that treats bone loss by improving osteoblast function. iBP releases repression of Wnt/β-catenin signaling, enhancing bone formation and repair in aging, trauma, and disease models.
- Liangyu Xing
- Jinxin Xu
- Xudong Wu